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The world seems to be recovering at this time, especially because of the 2019 global coronavirus
disease pandemic (COVID-19) caused by the Coronavirus 2 virus (SARS-CoV-2). This virus is
similar to other β-coronaviruses through several steps to enter and bind angiotensin-converting
enzyme 2 (ACE2) as the main receptor. This binding, particularly in the respiratory epithelium
and alveoli of the lungs, affects harmony in human host cells. No specific vaccines and antivirals
are available to date as drug investigations are still ongoing. However, many Indonesians
consume herbal medicine, especially 'empon-empon' containing the Zingiberaceae family, to
protect their health from COVID-19. So far, herbal medicine has shown good results to protect
the Indonesian people in fighting SARS-CoV-2 empirically. In this review, we describe the
characteristics of SARS-CoV-2, herbal ingredients that are active in fighting COVID-19, and
applied nanotechnology challenges to COVID-19. Therefore, it is proposed to develop herbal
medicine with a nanotechnology approach to increase the efficacy and potential of herbal medicine
in fighting COVID-19. Moreover, the development of nanotechnology for Indonesian jamu will
increase the value of Indonesian jamu and raise its reputation in the world.
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INTRODUCTION
The COVID-19 pandemic has become a world problem
as a global pandemic, where this case was first discovered
in Wuhan Province, China, in December 2019 (Khanna
et al., 2020)(Munster et al., 2020). The new coronavirus
is the sole agent causing a new infectious disease known
as severe acute respiratory syndrome coronavirus2
(SAR-Cov2). Coronavirus-2 is the seventh strain of
the Coronaviridae family (Fuzimoto & Isidoro, 2020;
Khanna et al., 2020). Coronavirus infections, including
SARS-CoV2, can cause death due to pulmonary
respiratory failure due to systemic cytokine storms (Liu
& Ying, 2020).
Secretion of several cytokines and mediators, such as
interleukin (IL) -1β, IL-6, IL-7, IL-8, IL-18, interferon
(IFN) -γ, tumor necrosis factor (TNF) -α, monocyte
chemoattractant peptide (MCP) -1, and granulocytecolony stimulating factor (G-CSF) have been shown
to increase in COVID-19 patients (Borish & Steinke,
2003; Liu & Ying, 2020). In addition, pro-inflammatory
cytokines play an important role in the process of disease
pathogenesis. Production of IL-1β occurs following
viral attachment to a receptor such as a toll (TLR) and
activation of the inflammasome. Elevated IL-6 levels
are associated with the development of COVID-19, and

monitoring of this cytokine may be a potential marker
in the prognosis of high-risk patients. TNF-α also plays
a stimulating role in the development of inflammation
and increases in the blood and peripheral tissues of
COVID-19 patients (Borish & Steinke, 2003; Khanna
et al., 2020). Studies on inflammatory diseases, such as
Multiple sclerosis (MS), Inflammatory bowel disease
(IBD), Rheumatoid arthritis (RA), and Ankylosing
spondylitis (AS) have shown that increased production
of IL-1β, IL-6, IL-18, and TNF -α is directly related to
disease activity. Therefore, it is speculated that the same
applies to COVID-19, and the severity of the disease
may be related to the production of inflammatory
cytokines. The study was conducted to overcome this
global pandemic to find drugs and antivirals (Liu &
Ying, 2020).
There is no specific antiviral recommended, there is no
vaccine available, and there is no medication approved
for the treatment of COVID-19 being today. At present,
the treatment is focused on the symptomatic of the
disease, and the patients who have a severe infection are
treated by oxygen therapy. In respiratory failure cases,
mechanical ventilation is needed, while hemodynamic
support is crucial for septic shock management (Hamid
et al., 2020).
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To treat COVID-19, the clinicians are using some
of the drugs which potent to overcome this disease,
not only the common antiviral such as remdesivir,
favipiravir, and lopinavir-ritonavir that used against
COVID-19 but also antimalarial such as chloroquine
and hydroxychloroquine. As adjuvant therapies,
dexamethasone and acetaminophen are using to fight
SARS-CoV-2 as well. All of them are displaying
acceptable outcomes; nevertheless, they still need more
investigations to have the best treatment for COVID-19
(Pooladanda et al., 2020). So far, the main treatment for
SARS-CoV-2 is using antivirals that prevent the virus
from entering the cells and avoiding it from replication
and the movement of infected cells to the others.
Meanwhile, antibiotics have no contribution to defeating
SARS-CoV-2 directly, but they could be helped if there
is a secondary bacterial infection due to COVID-19 (Abd
El-Aziz & Stockand, 2020). All of the compounds that
have a good potent for COVID-19 are being examined
mainly regarding the efficacy and the safety to beat
2019-nCoV. One of the most promising compounds is
remdesivir, an antiviral drug with an action mechanism
via terminating the RNA transcription prematurely, then
inhibits the viral replication result in disturbs the ability
of the virus to reproduce themselves (Jean et al., 2020).
Another alternative that researchers have taken to
address this case is to use convalescent plasma (CP) to
treat COVID-19, the classic adaptive immunotherapy
that has been used to prevent and treat many infectious
diseases for more than one hundred years. This plasma
treatment could be more effective for COVID-19
patients in the early stages before the virus can do more
serious damage to the lungs. CP is a promising and
safe, effective method for the treatment of recurring and
recurring pathogens, especially in the absence of proven
antiviral compounds or vaccines (Rojas et al., 2020).
Concerning this approach, the FDA has permitted the
use of blood plasma from patients who have recovered
from COVID-19 with high titers of antibody immune
response (Chen et al., 2020).
Researchers around the world are not only exploiting
specific vaccines and antivirals chemically and
biotechnology but also exploring natural products and/or
herbal medicines to treat COVID-19 (Ang et al., 2020).
The various viral infection steps and replication can be
inhibited by natural products, although the mechanisms
are not yet fully characterized. Natural products contribute
to reducing morbidity and mortality due to 2019-nCoV
infection through their function as immunomodulators
and suppressing the inflammatory process (McKee et
al., 2020). Compounds that have the potential to inhibit
coronavirus infection in humans include quercetin,
myricetin, psoralidin, caffeic acid, tryptanthrin, lycorine,
scutellarein, silvestrol, saikosaponin, isobavachalone,
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and griffithsin. If the therapeutic activity of lycorine as
an antiviral is not more than the level of plasma toxic
concentration, this compound could be a good choice
against the coronavirus. However, small molecules
identified as the most potent for coronavirus inhibitors
are categorized as polyphenols, which consist of
conjugated fusion rings (Mani et al., 2020).
Known as a country that has a large biodiversity,
Indonesian researchers also hardly exploit natural
products for the treatment of COVID-19. A typical
Indonesian natural product called jamu which has
been practiced for centuries to maintain health and
treat diseases. During the pandemic, many people in
Indonesia consumed herbal medicine as a weapon to
combat SARS-CoV-2 and sofar, they have been healthy.
However, the pharmacological activity associated with
herbal medicine is quite abundant according to empirical
data, so it is necessary to carry out further research to
prove its efficacy scientifically and to ensure its safety
(Elfahmi et al., 2014). To prevent cytokine storms,
residents in several countries use herbs that have antiinflammatory activity, one of which is Indonesia.
People in Indonesia from generation to generation know
and consume traditional medicine or better known as
jamu. Jamu, which comes from the ancient Javanese
word "jampi" (magic potion), is commonly consumed
to relieve pain and inflammation or to treat chronic
diseases, such as rheumatism and cancer. In Indonesia,
hundreds of ethnic groups have developed their own
traditional recipes, most of which are derived from
medicinal plants. These plant-based medicines contain
one ingredient or a mixture of several elements. Plants in
the Zingiberaceae (ginger) family, including Curcuma,
Kaempferia, Zingiber, Alpinia, Elattaria, and Costus,
have become mainstay elements in herbal medicine,
along with other vegetable ingredients. Consumption of
herbal medicine during the Coronavirus Disease 2019
(COVID-19) pandemic increased sharply, resulting
in an imbalance in supply with the demand for these
ingredients. Jamu, which is a traditional Indonesian
medicine that has been known from generation to
generation, is thought to increase immunity, making it the
most popular alternative treatment during this pandemic.
Nanotechnology development to increase antiviral
activity and many natural products have been developed in
dealing with COVID -19. Nanotechnology development
can be adapted to detect, treat, and prevent this disease
(Chan, 2020). In addition, nanoparticles can enhance the
therapeutic effect and minimize drug side effects. The
properties of nanoparticles are significant in antiviral
treatment where high drug concentrations are required
and overcome their limitations, such as bioavailability
(Milovanovic et al., 2017).
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Based on the description above, this review presents
the results of nanotechnology modification to increase
the efficacy of herbal medicine against SARS-CoV-2.
Preparing jamu in nanotechnology will increase the
value of the herbal medicine itself and provide a higher
bioavailability as an alternative to fight COVID-19.
METHODS
This literature review was performed using the google
search engine to find relevant references. The search
terms encompass ‘COVID-19’, ‘nanomedicine’, ‘herbal
nanoformulations’, ‘herbal nanoparticles’, ‘jamu’,
‘natural products’, ‘herbal medicine’, and ‘herbal
nanotechnology’. The period time for searching the
references for this review is 11 May 2020 to 31 October
2020.
RESULTS AND DISCUSSION
The Characteristics of SARS-CoV-2
The best way to treat COVID-19 is by knowing the
characteristics of SARS-CoV-2 first, clearly. SARSCoV-2 is the seventh coronavirus that is known to cause
human disease. Coronavirus (CoV) is a group of huge
and enveloped viruses with positive-sense, singlestranded RNA genomes. CoV is a zoonotic pathogen
that can infect humans via inter-species transmission.
This virus could be divided into four types: alpha, beta,
gamma, and delta coronavirus (Wang et al., 2020).
Human coronavirus are dominatingly associate with
upper respiratory tract illness with the range from mild to
moderate condition include the common cold (Vellingiri
et al., 2020). CoV represents a continuous pandemic
threat; humans have experienced two CoV-related health
security crises since 2002 (Chang et al., 2020), i.e. severe
acute respiratory syndrome coronavirus (SARS-CoV)
which appeared in China and the middle east respiratory
syndrome coronavirus (MERS-CoV) which emerged in
Saudi Arabia in 2012 (El Zowalaty & Järhult, 2020).
Both SARS-CoV and SARS-CoV-2 are part of the
β-genus of CoV. An envelope-anchored spike protein
mediates CoV and goes through into the host cells by
binding to the host receptor firstly and after that merge
the viral and the host membranes (Shereen et al., 2020).
A fined receptor-binding domain (RBD) of SARSCoV spike particularly recognizes its host receptor
angiotensin-converting enzyme 2 (ACE2) within the
respiratory epithelium and alveoli of the lungs (Yan.
et al., 2020). When compared with previously isolated
SARS-CoV strains, 2019-nCoV tends to use the human
ACE2 less efficiently than human SARS-CoV, which
was found in 2002. But SARS-CoV-2 likely uses human
ACE2 is more efficient than human SARS-CoV, which
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emerged in 2003. Since the ACE2-binding interaction
has proven to be one of the foremost vital determinants
of SARS-CoV infectivity, SARS-CoV-2 has developed
the capacity to infect humans and several capabilities to
transmit among humans (Wan et al., 2020).
Processing of Transmission of SARS COV-2 to Host
Cells
The process of SARS-CoV2 infection in host cells
requires a special receptor, the ACE2 receptor. The
interaction process between viral proteins and host cell
ACE2 receptors is the first step in infection. Henceforth,
the virus will have access to the host cytosol by carrying
out proteolytic cleavage, where this process is influenced
by the amount of acid from the spike protein by cathepsin
or other proteases (Nugraha et al., 2020). The spike
protein cleavage process occurs at two sites in the S2
portion. The first cleavage has a function of separating
the RBD domains with S protein fusion, and the second
cleavage serves to expose the fusion or splitting peptides
in S2. The fusion between the virus and the host cell
usually occurs within the endosome, which is acidified.
This process is followed by the joining of two heptad
replicates in S2 to form a six-helix antiparallel bundle.
Overall, the occurrence of new S1 and S2 insertions is
likely to influence the increase in spike protein cleavage
by some proteases beyond that for other SARS-like
viruses. The formation of the bundle leads to the mixing
of the viral cell membrane and the host cell and results
in the fusion and release of the viral genome into the
cytoplasm (Huang et al., 2020; Jaimes et al., 2020).
Jamu for COVID-19
Naturally, there are hundreds of herbs that have been
known to possess a significant amount of antiviral
activity when used. They may be readily available in the
garden or in the local market, and the others may prove
quite hard to find. Olive leaf, balm from lemon leaf,
ginger, chlorella, chamomiles, cayenne pepper, bilberry,
black cohosh, chili, garlic, astragalus, licorice root, etc.
are known used as antiviral, traditionally (James, 2015).
More advances, Traditional Chinese Medicine (TCM)
was used to prevent and treat SARS in 2003 and also for
the treatment of H1N1 infection in 2009. According to
these experiences, TCM has been widely used in Chinese
hospitals now to treat COVID-19. So far, the intervention
of TCM can reduce the severe symptoms of patients (Xu
& Zhang, 2020). However, the observation on SARS
patients with emerging COVID-19 treated by TCM
excluded the safety aspect. Considering the information
that several herbs used in the TCM contain nephrotoxins
and mutagens; meanwhile, the toxicological properties
of most Chinese herbal medicines must still be fully
understood (Yang et al., 2020).
E-ISSN 2477-0612
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Many natural products have good efficacy against viral
infection as they can influence the role of viral proteins
associated with virulence. Most of them have a common
mechanism as an antiviral agent by inhibiting the viral
replications. Chemical compounds from natural products
such as lycorine, homoharringtonine, silvestrol, ouabain,
tylophorine, and 7-methoxycrptopleurine have antiviral
activity in the nanomolar concentration and could be
lead for further drug development (Islam et al., 2020).
During the pandemic, many people in Indonesia
consumed ‘empon-empon’ as an alternative to protect
themselves and to defeat COVID-19. ‘Empon-empon’
has a closed connection to jamu and more specific,
‘empon-empon’ is a part of jamu. ‘Empon-empon’ has
two meanings (Riswan & Sangat-Remantyo, 2002),
those are:
• Empon-empon is yard medicinal plants. Almost
every family in the village in Java island has its own
yard to cultivate medicinal plants. Hence, they can
reach ‘empon-empon’ easily and use it to protect
their health and curing their illness at any time.
• Empon-empon is also a group of medicinal plants
belonging to the ginger family (Zingiberaceae) such
as ginger (Zingiber officinale Roscoe), turmeric
(Curcuma longa L.), Javanese turmeric (Curcuma
xanthorriza), greater galingale (Kaempferia
galanga L.), and galingale (Alpinia galanga (L.).
Some of them are used for flavors, dyes, spices, and
ornamental plants.
Empon-empon
containing
bioactive
curcumin,
which has known for its therapeutic potential as an
antibacterial, antifungal, and antiviral (Moghadamtousi
et al., 2014). Curcumin is a complex molecule with
numerous biological targets and diverse cellular effects,
such as anti-inflammation, antioxidant, and anti-cancer.
Furthermore, curcumin is non-toxic for humans at
high doses (Epstein et al., 2010). Conforming to these
investigations, ‘empon-empon’ has a good promising
as a therapeutic agent for the treatment of COVID-19.
Herbal medicine consists of several herbal mixtures,
which are formulated with certain comparisons based on
hereditary experiences. Herbal plants, as raw materials
for herbal medicine, have been proven to have antiviral,
anti-inflammatory, antibacterial activity, and so on.
Several studies were conducted to prove that herbal
plants, especially herbs, can be used as an alternative to
the prevention and antiviral treatment of SAR CoV-2,
either through pre-clinical or clinical approaches. Some
herbal raw material plants as candidates for SAR CoV-2
antiviral can be seen in Table 1.
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Nanotechnology for COVID-19
Nanotechnology approaches have been explored
as a therapeutic agent against coronavirus, include
nanomaterial, nanoparticles, nanocomposites, etc. The
development of Ag nanomaterials is a novel therapeutic
approach to fight the alpha-CoV porcine epidemic
diarrhea virus (PEDV) was first introduced in 2018. This
study illustrated that Ag2S nanoclusters (NCs) might
control the proliferation of PEDV in treated Vero cells.
The result showed that prevention of the viral growth
and inhibition of synthesis of viral negative-strand RNA
is associated with the treatment with Ag2S NCs. The
Ag2S NCs also demonstrated definitely govern interferon
(IFN)-stimulating gene proliferation and clearly regulate
the expression of pro-inflammatory cytokines. These
processes provoked the protection of the cells from
PEDV infection and proposed that Ag2S NCs could be a
great choice as a therapy tool for the next investigation
(Du et al., 2018).
Nanoformulation has been deployed for diphyllin as
a therapeutic agent to cure feline infectious peritonitis
(FIP), disease because of feline coronavirus. By
inhibiting the acidification of endosomal in fcwf-4cells, diphyllin is a vacuolar ATPase that could halt the
uncoating of the virus and break the cellular virus entry.
Diphyllin formulated with poly(ethylene glycol)-blockpoly(lactide-coglycolide) as a nanocarrier improved the
diphyllin inhibitory activity against FIP and increased the
safety profile. This study displayed that nanoformulation
of diphyllin was successful in defeating coronavirus
and the results suggested that the approach could be a
promising treatment to overcome CoV infection (Hu
et al., 2017). Furthermore, a nanospheres/microspheres
(NS/MS) using a device from biopolymeric material
having a great promising to beat coronavirus was
developed to tackle human coronavirus NL63 (Chen et
al., 2016).
Thereby, it can be concluded that nanotechnology
could improve antiviral applications against vary of
coronavirus. Nonetheless, it is needed more studies
about the treatment for COVID-19 using nanomedicines,
deeply, and comprehensively (Nikaeen et al., 2020).
Nanotechnology in Jamu
Nanotechnology is identic to nanoparticles; in the nano
size, particles have different properties as compared to
the macro size. The role of nanoparticles is applied to all
of the matter, include natural products. The effectiveness
of natural products in the prevention and treatment
of diseases could be improved by making them into
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Table 1. Herbal raw material plants as candidates for SAR CoV-2 antiviral
Material

interaction of active compounds
Active compound Prediction
with SAR-Cov-2

References

Zingiber officinale

6 - Gingerol

(Nugraha et al., 2020;
Rathinavel et al., 2020)

Black pepper

Piperdardiine

Curcuma longa

Curcumin

Curcuma longa

Xanthorrhizol

Gingerol exhibits binding affinity of -11.4082
KJ/mol, -12.9523 KJ/mol and -12.8835 KJ/
mol with COVID-19 viral RNA binding
protein (6W4B), N Terminal RNA Binding
Protein (6VSB), Spike glycoprotein (6M3M)
respectively. Molecular interaction between
COVID-19 viral spike glycoprotein with
Gingerol forms hydrogen-bonded interaction
with Glu63, Arg89, Thr92, Asp129 residues
and form non bonded interaction with Glu63,
Lys66, Arg89, Thr92, Leu168, Pro169 residues
of COVID-19 spike glycol protein.
Molecular interaction between COVID-19 viral
RNA binding protein with Gingerol makes
hydrogen bonded interaction with Val42,
Pro58, Ser60, Thr68 residues and form non
bonded interaction with Arg40, Phe41, Val42,
Phe57, Pro58, Lys59, Ser60, Ile66, Thr68, Ile92
residues of COVID-19 spike glycol protein.
Piperdardiine exhibited interactions with
COVID19 and the residues SER46, MET49,
HIE41, GLN189, ARG189, ASP187, MET165,
HIE164, THR24, THR25, LEU27, ASN142,
and GLY143 play a crucial role in binding with
ligands.
The anti-inflammatory mechanism of curcumin
is to inhibit the production and release of proinflammatory cytokines, such as IL-1, IL-6,
IL-8, TNF-a. Meanwhile, dissolved curcumin
directly into the lungs dramatically reduced
the pro-inflammatory cytokines IL-1b, IL-6,
TNF-a in LAB cells, lungs and serum of mice
with severe pneumonia caused by Klebsiella.
In addition, curcumin also decreases the
expression of many other inflammatory
mediators, including MCP1 (CCL2), MIPI1
(CCL3), GROa (CXCL1), GROb (CXCL2),
IP10 (CXCL10), SDF1 (CXCL12), MMP-2,
IFN-g., and MMP-9, which regulates immune
cell activity and inflammatory response and
increases fibrosis in the lungs after infection.
Xanthorrhizol has anti-inflammatory activity by
inhibiting inflammatory cytokines in adipose
tissue and expression of tumor necrosis factor
(TNF-α). Research has shown that xanthorrhizol
prevents recruitment of immune cells into
adipose tissue to downregulate inflammatory
cytokine genes. Xanthorrhizol also has the
activity of reducing interleukin (IL-1β) gene
expression in muscle. Other studies have shown
that xanthorrhizol can reduce serum IL-6 levels
and increase serum transformation growth factor
(TGF-β) in patients with SLE with hypovitamin
D.

(Nandi & Mitra, 2020;
Rajagopal et al., n.d.)

(Liu & Ying, 2020;
Nugraha et al., 2020)

(Kim et al., 2014;
Nugraha et al., 2020)
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Table 1. (continued)
Material

interaction of active compounds
Active compound Prediction
with SAR-Cov-2

Citrus fruit

Naringin

Naringin pretreatment significantly inhibited (Cheng et al., 2020)
LPS-induced expression of HMGB1 protein
and proinflammatory cytokines (COX-2, iNOS,
IL-1β and IL-6) expression in vitro. HMGB1
is a ubiquitous DNA-binding core protein and
can be actively released by immune cells, such
as macrophages and monocytes, following
inflammatory stimuli. HMGB1 also acts as a
pro-inflammatory cytokine and regulates the
storm of cytokines, up-regulating cytokines
such as TNF-α, IL-6, IL-1β, and IL-8.

nanoparticles. One of the main reasons regarding the
effectiveness of nanoparticles is the improvement of
bioavailability. Having a good bioavailability will
improve the pharmacokinetic profile that results in better
therapeutic effects (Zhang et al., 2015).
Sulistyo and colleagues (2017) observed that green
tea nanoparticles have better effects in ironized mouse
model thalassemia as compared to the green tea as a
free compound. The green tea extract prepared into
nanoparticles using chitosan as a carrier crosslinked with
sodium tripolyphosphate (Sulistyo et al., 2017).
Another benefit of the application of nanoparticles in
the delivery of natural compounds is the system can
reach the specific target sites such as certain tissues,
organs, and cells. Delivery of natural products with
nanoparticles device gives critical impacts, especially
minimizing the adverse effects of the active substances.
Using a self-nano emulsifying drug delivery system
(SNEDDS), quercetin demonstrated a protective effect
against liver damage. The histopathological observation
displayed that the inflammatory infiltrations induced by
paracetamol significantly ameliorated (Ahmed et al.,
2014).
Nanoparticles can also deliver the natural products with
controlled release, mainly by formulating the herbal with
a polymer as a carrier. Formulation of acerola, guava,
and passion fruits by-products inside PLGA (poly(DLlactide-co-glycolide) matrix demonstrated an initial burst
then gradually followed by a slower rate. The release of
the drug from the nanoparticles at a controlled rate is a
crucial key since the drug release kinetics determine the
concentration of the drug in the target site (Silva et al.,
2014).
All of the natural products in Indonesia which have
therapeutic effects as a medicine empirically are
categorized as jamu. Accordingly, the efficacy and the
E-ISSN 2477-0612
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value of jamu should be improved using nanotechnology
approaches. Various methods of preparation of
nanotechnology approaches could be applied in jamu
i.e., nanosuspension, nanopolymerization, oil, solvent,
and surfactant-co-surfactant mixture, self-nanoemulsion,
nanoprecipitation, ultrasonication, solvent emulsion and
evaporation, hot homogenization, nanoencapsulation,
nanofiber fabrication, electrospinning, and spray drying
(Gopi & Amalraj, 2016).
CONCLUSION
Jamu is a traditional Indonesian medicine made from
a mixture of several plants such as ‘empon-empon’,
which has been used for generations in Indonesia as a
supplement or medicine to increase endurance and cure
diseases. During the pandemic, many people in Indonesia
consumed ‘empon-empon’ to protect themselves
from SARS-CoV-2. Further evidence-based research
in Jamu is needed to conform its efficacy. Through
a nanotechnology approach, the value and potential
of Jamu can be increased and become a promising
therapeutic option for the treatment of COVID-19.
Moreover, the development of nanotechnology for
Indonesian jamu will increase the value of Indonesian
jamu and raise its reputation in the world.
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